{"prompt": "['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 78 of 92', 'CR845-CLIN3102', 'The study monitor or other authorized representatives of the Sponsor may inspect all', 'documents and records required to be maintained by the Investigator, including, but not', 'limited to, medical records (office, clinic, or hospital) and pharmacy records for the', 'participants in this study.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 80 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 79 of 92', 'CR845-CLIN3102', '11.0', 'Data Handling and Quality Assurance', 'All participant data relating to the study will be recorded on eCRFs unless transmitted to', 'the Sponsor or designee electronically (eg, laboratory data). No data are to be recorded', 'directly in the eCRFs (eg, all data will have a unique source). The Investigator is', 'responsible for verifying that data entries are accurate and correct by physically or', 'electronically signing the eCRF.', 'The Investigator must maintain accurate documentation (source data) that supports the', 'information entered in the eCRF.', 'The Investigator must permit study-related monitoring, audits, IRB/Independent Ethics', 'Committee review, and regulatory agency inspections and provide direct access to source', 'data documents.', 'The Sponsor or designee is responsible for the data management of this study, including', 'quality checking of the data.', 'Study monitors will perform ongoing source data verification to confirm that data entered', 'into the eCRF by authorized site personnel are accurate, complete, and verifiable from', 'source documents; that the safety and rights of participants are being protected; and that', 'the study is being conducted in accordance with the currently approved protocol and any', 'other study agreements, ICH-GCP, and all applicable regulatory requirements.', 'Records and documents, including signed ICFs, pertaining to the conduct of this study', 'must be retained by the Investigator for 2 years after the marketing approval of the study', 'drug or after discontinuing clinical development unless local regulations or institutional', 'policies require a longer retention period. No records may be destroyed during the', 'retention period without the written approval of the Sponsor. No records may be', 'transferred to another location or party without written notification to the Sponsor. If the', 'Investigator withdraws from the responsibility of keeping the study records, custody must', 'be transferred to a person willing to accept the responsibility. If a custodial change or a', 'change in record location occurs, Cara Therapeutics must be notified in writing.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 81 of 95']['Cara Therapeutics, Inc.', 'Difelikefalin (IV CR845)', 'CR845-CLIN3102', 'Clinical Study Report - Double-blind Phase', 'Cara Therapeutics Inc.', 'Confidential', 'Page 80 of 92', 'CR845-CLIN3102', '12.0', 'Administrative Procedures', '12.1', 'Protocol Adherence', 'It is vital to the success of the study that the Investigator adhere to the details of the', 'protocol, and thus to keep to a minimum the number of cases later classified as', '\"incomplete,\" \"unusable,\" or \"not evaluable.\" If, in the interest of safety and/or', 'well-being of a particular patient, it is necessary to depart from the protocol, then that', 'protocol deviation will pertain to that individual patient only and will be documented.', 'Protocol deviations due to lack of patient compliance must also be documented.', 'The site monitor will review protocol deviations throughout the course of monitoring', 'visits and document new findings of deviations. The monitor will notify the Investigators', 'of deviations verbally or in writing. The IRB should be notified of all protocol deviations', 'in a timely manner according to IRB requirements.', '12.2', 'Publication of Study Findings', 'All information regarding CR845 provided by Cara Therapeutics to the Investigator is', 'privileged and confidential information. By conducting this study, the Investigator', 'affirms to the Sponsor that he/she will maintain, in strict confidence, information', 'furnished by the Sponsor, including data generated from this study and preliminary', 'laboratory results, except as exempted for regulatory purposes. All data generated during', 'the conduct of this study are owned by Cara Therapeutics. The Investigator agrees to use', 'the information to accomplish the study and will not use it for other purposes without', 'written permission from Cara Therapeutics. Partial or full data or results from this study', 'cannot be published without express written consent from Cara Therapeutics. It is', 'understood that there is an obligation to provide Cara Therapeutics with complete data', 'obtained during the study. The information obtained from the clinical study will be used', 'toward the development of CR845 and may be disclosed to regulatory authority, other', 'Investigators, corporate partners, or consultants, as required.', '21 December 2017', 'Version 1.0', 'CONFIDENTIAL', 'Page 82 of 95']\n\n###\n\n", "completion": "END"}